

# Emilio Perucca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1774469/publications.pdf>

Version: 2024-02-01

285  
papers

31,462  
citations

8181

76  
h-index

4774

169  
g-index

324  
all docs

324  
docs citations

324  
times ranked

19613  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cenobamate: A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability Profile in the Treatment of Epilepsy. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 394-403.	1.4	7
2	Web-based decision support system for patient-tailored selection of antiseizure medication in adolescents and adults: An external validation study. <i>European Journal of Neurology</i> , 2022, 29, 382-389.	3.3	7
3	The EpiPick algorithm to select appropriate antiseizure medications in patients with epilepsy: Validation studies and updates. <i>Epilepsia</i> , 2022, 63, 254-255.	5.1	6
4	Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?. <i>CNS Drugs</i> , 2022, 36, 113-122.	5.9	9
5	International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions. <i>Epilepsia</i> , 2022, 63, 1398-1442.	5.1	263
6	Introduction to the epilepsy syndrome papers. <i>Epilepsia</i> , 2022, 63, 1330-1332.	5.1	23
7	Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions. <i>Epilepsia</i> , 2022, 63, 1333-1348.	5.1	84
8	International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. <i>Epilepsia</i> , 2022, 63, 1443-1474.	5.1	81
9	ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. <i>Epilepsia</i> , 2022, 63, 1349-1397.	5.1	237
10	ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. <i>Epilepsia</i> , 2022, 63, 1475-1499.	5.1	148
11	The 50th anniversary of the Italian League Against Epilepsy (Lega Italiana Contro l'Epilessia). <i>Epilepsy and Behavior Reports</i> , 2022, 19, 100553.	1.0	0
12	Basal Ganglia Dymorphism in Patients With Aicardi Syndrome. <i>Neurology</i> , 2021, 96, e1319-e1333.	1.1	6
13	Optimal choice of antiseizure medication: Agreement among experts and validation of a web-based decision support application. <i>Epilepsia</i> , 2021, 62, 220-227.	5.1	13
14	FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force. <i>Epilepsia Open</i> , 2021, 6, 45-48.	2.4	32
15	The initial impact of the SARS-CoV-2 pandemic on epilepsy research. <i>Epilepsia Open</i> , 2021, 6, 255-265.	2.4	2
16	Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. <i>Neuropharmacology</i> , 2021, 185, 108442.	4.1	43
17	New paradigms for the treatment of pediatric monogenic epilepsies: Progressing toward precision medicine. <i>Epilepsy and Behavior</i> , 2021, , 107961.	1.7	4
18	Pediatric adverse reactions to antiseizure medications – An analysis of data from the Italian spontaneous reporting system (2001–2019). <i>Epilepsy and Behavior</i> , 2021, 119, 107989.	1.7	13

#	ARTICLE	IF	CITATIONS
19	A web-based algorithm to rapidly classify seizures for the purpose of drug selection. <i>Epilepsia</i> , 2021, 62, 2474-2484.	5.1	7
20	Epilepsy care during the COVID-19 pandemic. <i>Epilepsia</i> , 2021, 62, 2322-2332.	5.1	48
21	The pharmacological treatment of epilepsy: recent advances and future perspectives. <i>Acta Epileptologica</i> , 2021, 3, .	0.9	30
22	Selection of antiseizure medications for first add-on use: A consensus paper. <i>Epilepsy and Behavior</i> , 2021, 122, 108087.	1.7	6
23	Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. , 2021, 226, 107866.		27
24	Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. <i>Epilepsia</i> , 2021, 62, 285-302.	5.1	12
25	Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements. <i>BMC Neurology</i> , 2021, 21, 410.	1.8	8
26	Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review. <i>Epilepsy and Behavior</i> , 2020, 103, 106861.	1.7	12
27	Determination of Perampanel in Dried Plasma Spots: Applicability to Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 309-314.	2.0	5
28	Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*). <i>Trials</i> , 2020, 21, 957.	1.6	8
29	Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. <i>Epilepsia</i> , 2020, 61, 2365-2385.	5.1	45
30	A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. <i>Epilepsia</i> , 2020, 61, 1668-1677.	5.1	32
31	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1493-1500.	3.5	31
32	Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. <i>Epilepsia</i> , 2020, 61, 1082-1089.	5.1	42
33	Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy. <i>Epilepsia</i> , 2020, 61, e79-e84.	5.1	6
34	Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. <i>CNS Drugs</i> , 2020, 34, 795-800.	5.9	81
35	Antiepileptic Drug Teratogenicity and De Novo Genetic Variation Load. <i>Annals of Neurology</i> , 2020, 87, 897-906.	5.3	9
36	Does screening for adverse effects improve health outcomes in epilepsy?. <i>Neurology</i> , 2020, 95, e239-e246.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Response: Cannabidiol antiseizure activity and its interactions with clobazam: â€œItâ€™s dÃ©jÃ  vu all over againâ€-Yogi Berra. <i>Epilepsia</i> , 2020, 61, 1793-1794.	5.1	0
38	Time to Start Calling Things by Their Own Names? The Case for Antiseizure Medicines. <i>Epilepsy Currents</i> , 2020, 20, 69-72.	0.8	25
39	30 years of second-generation antiseizure medications: impact and future perspectives. <i>Lancet Neurology</i> , The, 2020, 19, 544-556.	10.2	134
40	Keeping people with epilepsy safe during the COVID-19 pandemic. <i>Neurology</i> , 2020, 94, 1032-1037.	1.1	116
41	Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. <i>Drugs</i> , 2019, 79, 1435-1454.	10.9	101
42	Classification as autonomic versus sensory seizures. <i>Epilepsia</i> , 2019, 60, 2003-2005.	5.1	4
43	Novel therapies for epilepsy in the pipeline. <i>Epilepsy and Behavior</i> , 2019, 97, 282-290.	1.7	28
44	Novel study design to assess the efficacy and tolerability of antiseizure medications for focal-onset seizures in infants and young children: A consensus document from the regulatory task force and the pediatric commission of the International League against Epilepsy (ILAE), in collaboration with the Pediatric Epilepsy Research Consortium (PERC). <i>Epilepsia Open</i> , 2019, 4, 537-543.	2.4	20
45	Declining malformation rates with changed antiepileptic drug prescribing. <i>Neurology</i> , 2019, 93, e831-e840.	1.1	69
46	Neurovascular Drug Biotransformation Machinery in Focal Human Epilepsies: Brain CYP3A4 Correlates with Seizure Frequency and Antiepileptic Drug Therapy. <i>Molecular Neurobiology</i> , 2019, 56, 8392-8407.	4.0	16
47	2017 International League Against Epilepsy classifications of seizures and epilepsy are steps in the right direction. <i>Epilepsia</i> , 2019, 60, 1040-1044.	5.1	15
48	Seizure-alerting behavior in dogs owned by people experiencing seizures. <i>Epilepsy and Behavior</i> , 2019, 94, 104-111.	1.7	11
49	Identifying mutations in epilepsy genes: Impact on treatment selection. <i>Epilepsy Research</i> , 2019, 152, 18-30.	1.6	93
50	Low risk pragmatic trials do not always require participantsâ€™ informed consent. <i>BMJ: British Medical Journal</i> , 2019, 364, l1092.	2.3	28
51	Validated outcome of treatment changes according to International League Against Epilepsy criteria in adults with drug-resistant focal epilepsy. <i>Epilepsia</i> , 2019, 60, 1114-1123.	5.1	23
52	A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV). <i>Epilepsy Research</i> , 2019, 153, 66-67.	1.6	3
53	Teratogenicity of antiepileptic drugs. <i>Current Opinion in Neurology</i> , 2019, 32, 246-252.	3.6	101
54	Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?. <i>Epilepsia</i> , 2019, 60, 175-183.	5.1	12

#	ARTICLE	IF	CITATIONS
55	Antiepileptic drugs: evolution of our knowledge and changes in drug trials. <i>Epileptic Disorders</i> , 2019, 21, 319-329.	1.3	28
56	Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. <i>Lancet Neurology</i> , The, 2018, 17, 530-538.	10.2	348
57	Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive peramppanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. <i>Epilepsia</i> , 2018, 59, 866-876.	5.1	74
58	Genetic testing to prevent adverse reactions to antiepileptic drugs. <i>Neurology</i> , 2018, 90, 155-156.	1.1	3
59	A simple and rapid HPLC-UV method for the determination of retigabine in human plasma. <i>Biomedical Chromatography</i> , 2018, 32, e4168.	1.7	5
60	From clinical trials of antiepileptic drugs to treatment. <i>Epilepsia Open</i> , 2018, 3, 220-230.	2.4	29
61	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. <i>Epilepsia</i> , 2018, 59, 1811-1841.	5.1	108
62	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. <i>Epilepsia</i> , 2018, 59, 1842-1866.	5.1	44
63	Drug interactions with carbamazepine: An ever expanding list?. <i>Epilepsy Research</i> , 2018, 147, 119-120.	1.6	4
64	No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia risk—An analysis of Finnish health register and German health insurance data. <i>Epilepsia</i> , 2018, 59, 1303-1306.	5.1	6
65	EURAP registry: inadequate monitoring of prescribed drugs in pregnancy — Authors' reply. <i>Lancet Neurology</i> , The, 2018, 17, 741-742.	10.2	5
66	No Evidence of a Causal Role of Antiepileptic Drug Treatment with Regard to the Development of Dementia. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1850-1852.	2.6	4
67	Advocacy for children with epilepsy: Leveraging the WHO resolution. Advocacy Task Force, Commission of Pediatrics, International League Against Epilepsy. <i>Epilepsia Open</i> , 2018, 3, 167-174.	2.4	5
68	Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). <i>Epilepsia</i> , 2017, 58, 181-221.	5.1	92
69	ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. <i>Epilepsia</i> , 2017, 58, 512-521.	5.1	3,464
70	Maternal and fetal outcomes associated with vagus nerve stimulation during pregnancy. <i>Epilepsy Research</i> , 2017, 137, 159-162.	1.6	20
71	A Tribute to Steve White. <i>Neurochemical Research</i> , 2017, 42, 1867-1868.	3.3	1
72	How long for epilepsy remission in the ILAE definition?. <i>Epilepsia</i> , 2017, 58, 1486-1487.	5.1	4

#	ARTICLE	IF	CITATIONS
73	Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?. Journal of Epilepsy Research, 2017, 7, 61-76.	0.4	176
74	Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from <scp>EURAP</scp>. Epilepsia, 2016, 57, e173-7.	5.1	65
75	An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 685-689.	1.9	3
76	Epilepsy, seizures, physical exercise, and sports: A report from the <scp>ILAE</scp> Task Force on Sports and Epilepsy. Epilepsia, 2016, 57, 6-12.	5.1	145
77	Not all that glitters is gold: A guide to the critical interpretation of drug trials in epilepsy. Epilepsia Open, 2016, 1, 9-21.	2.4	25
78	Commentary: Message from the ILAE president. Epilepsia Open, 2016, 1, 8-8.	2.4	0
79	Challenges in the clinical development of new antiepileptic drugs. Pharmacological Research, 2016, 103, 95-104.	7.1	68
80	Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurology, The, 2016, 15, 210-218.	10.2	197
81	The current state of epilepsy guidelines: A systematic review. Epilepsia, 2016, 57, 13-23.	5.1	54
82	The safety of generic substitution in epilepsy. Lancet Neurology, The, 2016, 15, 344-345.	10.2	3
83	Antiepileptic drug use and epileptic seizures in nursing home residents in the Province of Pavia, Italy: A reappraisal 12 years after a first survey. Epilepsy Research, 2016, 119, 41-48.	1.6	10
84	Developing clinical practice guidelines for epilepsy: A report from the ILAE Epilepsy Guidelines Working Group. Epilepsia, 2015, 56, 1859-1869.	5.1	24
85	A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy. Epilepsia, 2015, 56, 1162-1173.	5.1	44
86	Availability of antiepileptic drugs across Europe. Epilepsia, 2015, 56, e191-7.	5.1	12
87	From global campaign to global commitment: The World Health Assembly's Resolution on epilepsy. Epilepsia, 2015, 56, 1651-1657.	5.1	53
88	Epilepsy priorities in Europe: A report of the <scp>ILAE</scp> & <scp>IBE</scp> Epilepsy Advocacy Europe Task Force. Epilepsia, 2015, 56, 1687-1695.	5.1	81
89	Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: An in vitro study. Epilepsia, 2015, 56, 439-449.	5.1	23
90	Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Research, 2015, 111, 85-141.	1.6	161

#	ARTICLE	IF	CITATIONS
91	Dose-dependent teratogenicity of valproate in mono- and polytherapy. <i>Neurology</i> , 2015, 85, 866-872.	1.1	136
92	CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1269-1279.	3.3	42
93	Antiepileptic drugs and intrauterine death. <i>Neurology</i> , 2015, 85, 580-588.	1.1	84
94	Commentary: Why an International Epilepsy Day?. <i>Epilepsia</i> , 2015, 56, 170-171.	5.1	3
95	The pharmacogenomics of epilepsy. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1161-1170.	2.8	33
96	Is a separate monotherapy indication warranted for antiepileptic drugs?. <i>Lancet Neurology</i> , The, 2015, 14, 1229-1240.	10.2	36
97	Epilepsy: new advances. <i>Lancet</i> , The, 2015, 385, 884-898.	13.7	706
98	Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. <i>Epileptic Disorders</i> , 2014, 16, 409-431.	1.3	212
99	Off-Label Prescribing of Antiepileptic Drugs in Pharmacoresistant Epilepsy: A Cross-Sectional Drug Utilization Study of Tertiary Care Centers in Italy. <i>CNS Drugs</i> , 2014, 28, 939-949.	5.9	23
100	Commentary: Epilepsy is a Global Problem. <i>Epilepsia</i> , 2014, 55, 1326-1328.	5.1	16
101	The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: The PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. <i>Epilepsia</i> , 2014, 55, 893-900.	5.1	149
102	ILAE Official Report: A practical clinical definition of epilepsy. <i>Epilepsia</i> , 2014, 55, 475-482.	5.1	3,770
103	Gender issues in antiepileptic drug treatment. <i>Neurobiology of Disease</i> , 2014, 72, 217-223.	4.4	35
104	The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: A case-control study. <i>Epilepsy Research</i> , 2013, 103, 245-253.	1.6	19
105	Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of Age: An Update. <i>Clinical Pharmacokinetics</i> , 2013, 52, 627-645.	3.5	98
106	Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI). <i>Epilepsy Research</i> , 2013, 103, 2-30.	1.6	201
107	Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. <i>Epilepsia</i> , 2013, 54, 551-563.	5.1	599
108	Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 615-625.	2.8	30

#	ARTICLE	IF	CITATIONS
109	Optimizing antiepileptic drug treatment in tumoral epilepsy. <i>Epilepsia</i> , 2013, 54, 97-104.	5.1	77
110	What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? <i>Epileptic Disorders</i> , 2012, 14, 124-131.	1.3	34
111	Antiepileptic drug selection for people with HIV/AIDS: Evidence-based guidelines from the ILAE and AAN. <i>Epilepsia</i> , 2012, 53, 207-214.	5.1	47
112	Identification of new epilepsy treatments: Issues in preclinical methodology. <i>Epilepsia</i> , 2012, 53, 571-582.	5.1	219
113	The Pharmacology of New Antiepileptic Drugs. <i>CNS Drugs</i> , 2011, 25, 907-912.	5.9	28
114	Novel Medications for Epilepsy. <i>Drugs</i> , 2011, 71, 2151-2178.	10.9	60
115	Antiepileptic drug therapy: Does mechanism of action matter?. <i>Epilepsy and Behavior</i> , 2011, 21, 331-341.	1.7	117
116	Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 1013-1021.	3.7	33
117	New and forthcoming anti-epileptic drugs. <i>Current Opinion in Neurology</i> , 2011, 24, 159-164.	3.6	24
118	Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. <i>Epilepsia</i> , 2011, 52, 219-233.	5.1	140
119	A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. <i>Epilepsia</i> , 2011, 52, 802-809.	5.1	67
120	A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. <i>Epilepsia</i> , 2011, 52, e40-e44.	5.1	50
121	Determinants of health-related quality of life in pharmaco-resistant epilepsy: Results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. <i>Epilepsia</i> , 2011, 52, 2181-2191.	5.1	227
122	The pharmacological treatment of epilepsy in adults. <i>Lancet Neurology</i> , The, 2011, 10, 446-456.	10.2	259
123	Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. <i>Lancet Neurology</i> , The, 2011, 10, 609-617.	10.2	654
124	Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. <i>Epilepsy Research</i> , 2011, 94, 117-120.	1.6	24
125	A young woman with recurring seizures. <i>Neurosciences</i> , 2011, 16, 292-4.	0.1	0
126	Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , 2010, 51, 1069-1077.	5.1	3,400



#	ARTICLE	IF	CITATIONS
127	When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy?. <i>Lancet Neurology, The</i> , 2010, 9, 457-459.	10.2	6
128	Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. <i>Epilepsy Research</i> , 2010, 91, 273-282.	1.6	50
129	Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X). <i>Epilepsy Research</i> , 2010, 92, 89-124.	1.6	145
130	Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. <i>Epilepsia</i> , 2010, 51, 921-925.	5.1	35
131	Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drugâ€refractory epilepsy. <i>Epilepsia</i> , 2010, 51, 797-804.	5.1	160
132	When clinical trials make history: Demonstrating efficacy of new antiepileptic drugs as monotherapy. <i>Epilepsia</i> , 2010, 51, 1933-1935.	5.1	25
133	Epilepsy: seizures, syndromes, and survival. <i>Lancet Neurology, The</i> , 2009, 8, 10-12.	10.2	4
134	Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. <i>Lancet Neurology, The</i> , 2009, 8, 82-93.	10.2	412
135	Extended-Release Formulations of Antiepileptic Drugs: Rationale and Comparative Value. <i>Epilepsy Currents</i> , 2009, 9, 153-157.	0.8	43
136	Italian Consensus Conference on Epilepsy and Pregnancy, Labor and Puerperium. <i>Epilepsia</i> , 2009, 50, 7-23.	5.1	31
137	Cardiac function and antiepileptic drug treatment in the elderly: A comparison between lamotrigine and sustainedâ€release carbamazepine. <i>Epilepsia</i> , 2009, 50, 1841-1849.	5.1	55
138	Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures. <i>Epilepsia</i> , 2009, 50, 1891-1898.	5.1	9
139	What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NSâ€1209, and topiramate. <i>Epilepsia</i> , 2009, 50, 49-50.	5.1	86
140	Lacosamide. <i>CNS Drugs</i> , 2009, 23, 555-568.	5.9	72
141	Antiepileptic drugs and brain maturation: Fetal exposure to lamotrigine generates cortical malformations in rats. <i>Epilepsy Research</i> , 2008, 78, 131-139.	1.6	45
142	Lacosamide. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 973-974.	46.4	96
143	The treatment of the first seizure: The risks. <i>Epilepsia</i> , 2008, 49, 29-34.	5.1	9
144	Antiepileptic drugsâ€best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , 2008, 49, 1239-1276.	5.1	914

#	ARTICLE	IF	CITATIONS
145	Rufinamide: Clinical pharmacokinetics and concentrationâ€“response relationships in patients with epilepsy. <i>Epilepsia</i> , 2008, 49, 1123-1141.	5.1	244
146	Designing Clinical Trials to Assess Antiepileptic Drugs as Monotherapy. <i>CNS Drugs</i> , 2008, 22, 917-938.	5.9	34
147	Pregabalin for the management of partial epilepsy. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1211.	2.2	29
148	Changes in Lamotrigine Pharmacokinetics during Pregnancy and the Puerperium. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 544-547.	2.0	29
149	Changes in plasma levetiracetam concentrations in pregnant women and their breastfed infants. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 538-539.	2.5	3
150	Ageâ€“Related Changes in Pharmacokinetics: Predictability and Assessment Methods. <i>International Review of Neurobiology</i> , 2007, 81, 183-199.	2.0	24
151	Withdrawing antiepileptic drugs in seizure-free patients: what are the cognitive benefits?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 194-195.	2.5	1
152	A Novel Enantioselective Microassay for the High-Performance Liquid Chromatography Determination of Oxcarbazepine and Its Active Metabolite Monohydroxycarbamazepine in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 319-324.	2.0	17
153	Old versus new antiepileptic drugs: the SANAD study. <i>Lancet, The</i> , 2007, 370, 313.	13.7	18
154	Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 854, 63-67.	2.3	16
155	Idiosyncratic Adverse Reactions to Antiepileptic Drugs. <i>Epilepsia</i> , 2007, 48, 1223-1244.	5.1	321
156	Fetal Exposure to GABA-Acting Antiepileptic Drugs Generates Hippocampal and Cortical Dysplasias. <i>Epilepsia</i> , 2007, 48, 684-693.	5.1	109
157	An International Multicenter Randomized Double-Blind Controlled Trial of Lamotrigine and Sustained-Release Carbamazepine in the Treatment of Newly Diagnosed Epilepsy in the Elderly. <i>Epilepsia</i> , 2007, 48, 1292-1302.	5.1	201
158	Development of new antiepileptic drugs: challenges, incentives, and recent advances. <i>Lancet Neurology, The</i> , 2007, 6, 793-804.	10.2	303
159	Prenatal exposure to antiepileptic drugs. <i>Lancet, The</i> , 2006, 367, 1467-1469.	13.7	18
160	Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of Age. <i>Clinical Pharmacokinetics</i> , 2006, 45, 351-363.	3.5	113
161	ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. <i>Epilepsia</i> , 2006, 47, 1094-1120.	5.1	782
162	Increased Apparent Oral Clearance of Valproic Acid during Intake of Combined Contraceptive Steroids in Women with Epilepsy. <i>Epilepsia</i> , 2006, 47, 1569-1572.	5.1	59

#	ARTICLE	IF	CITATIONS
163	Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs. <i>Epilepsia</i> , 2006, 47, 16-20.	5.1	75
164	Clinically relevant drug interactions with antiepileptic drugs. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 246-255.	2.4	502
165	Active control trials: Endpoints beyond conventional efficacy and tolerability measures. <i>Epilepsy Research</i> , 2006, 68, 73-74.	1.6	3
166	The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. <i>Epilepsy Research</i> , 2006, 70, 153-160.	1.6	27
167	Pharmacokinetic Variability of New Antiepileptic Drugs at Different Ages. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 714-717.	2.0	35
168	Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: A pooled analysis of data from randomized clinical trials. <i>Epilepsy Research</i> , 2005, 64, 1-11.	1.6	67
169	An Introduction to Antiepileptic Drugs. <i>Epilepsia</i> , 2005, 46, 31-37.	5.1	135
170	Pharmacokinetic and Metabolic Investigation of Topiramate Disposition in Healthy Subjects in the Absence and in the Presence of Enzyme Induction by Carbamazepine. <i>Epilepsia</i> , 2005, 46, 378-384.	5.1	65
171	Birth defects after prenatal exposure to antiepileptic drugs. <i>Lancet Neurology</i> , The, 2005, 4, 781-786.	10.2	168
172	Predictability of metabolic antiepileptic drug interactions. , 2005, , 57-92.		6
173	Pregabalin as Adjunctive Treatment of Partial Seizures. <i>CNS Drugs</i> , 2005, 19, 273-274.	5.9	2
174	Overtreatment in Epilepsy. <i>CNS Drugs</i> , 2005, 19, 897-908.	5.9	69
175	Topiramate Pharmacokinetics in Children and Adults with Epilepsy. <i>Clinical Pharmacokinetics</i> , 2005, 44, 407-416.	3.5	59
176	Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. <i>Epileptic Disorders</i> , 2005, 7 Suppl 1, S14-21.	1.3	1
177	Revisiting phenobarbital for epilepsy. <i>BMJ: British Medical Journal</i> , 2004, 329, 1199-1200.	2.3	27
178	Navigating toward Fetal and Maternal Health: The Challenge of Treating Epilepsy in Pregnancy. <i>Epilepsia</i> , 2004, 45, 1171-1175.	5.1	97
179	Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. <i>Epilepsy Research</i> , 2004, 59, 155-165.	1.6	31
180	NICE guidance on newer drugs for epilepsy in adults. <i>BMJ: British Medical Journal</i> , 2004, 328, 1273-1274.	2.3	25

#	ARTICLE	IF	CITATIONS
181	Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. <i>Lancet Neurology</i> , The, 2003, 2, 347-356.	10.2	447
182	Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. <i>Lancet Neurology</i> , The, 2003, 2, 473-481.	10.2	359
183	Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. <i>Epilepsy Research</i> , 2003, 57, 1-13.	1.6	136
184	Interlaboratory Variability in the Quantification of New Generation Antiepileptic Drugs Based on External Quality Assessment Data. <i>Epilepsia</i> , 2003, 44, 40-45.	5.1	27
185	Serum Carbamazepine Concentrations in Elderly Patients: A Case-matched Pharmacokinetic Evaluation Based on Therapeutic Drug Monitoring Data. <i>Epilepsia</i> , 2003, 44, 923-929.	5.1	57
186	Current Trends in Antiepileptic Drug Therapy. <i>Epilepsia</i> , 2003, 44, 41-47.	5.1	22
187	Translating monotherapy trials into clinical practice: a look into the abyss. <i>Epilepsy and Behavior</i> , 2003, 4, 457-463.	1.7	9
188	Plasma Gabapentin Concentrations in Children With Epilepsy: Influence of Age, Relationship With Dosage, and Preliminary Observations on Correlation With Clinical Response. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 54-60.	2.0	29
189	Influence of Dosage, Age, and Co-medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 700-708.	2.0	41
190	The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?. <i>Epileptic Disorders</i> , 2003, 5 Suppl 1, S17-26.	1.3	10
191	Marketed New Antiepileptic Drugs: Are They Better Than Old-Generation Agents?. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 74-80.	2.0	54
192	Principles of pharmacotherapy of the epilepsies. , 2002, , 1301-1312.		3
193	Pharmacological and Therapeutic Properties of Valproate. <i>CNS Drugs</i> , 2002, 16, 695-714.	5.9	561
194	Challenges in the pharmacotherapy of the epilepsies. <i>Expert Review of Neurotherapeutics</i> , 2002, 2, 439-442.	2.8	1
195	Patient-tailored antiepileptic drug therapy: predicting response to antiepileptic drugs. <i>International Congress Series</i> , 2002, 1244, 93-103.	0.2	8
196	Clinical pharmacology and therapeutic use of the new antiepileptic drugs <i>Fundamental and Clinical Pharmacology</i> (2001) 15 405-417. <i>Fundamental and Clinical Pharmacology</i> , 2002, 16, 249-249.	1.9	1
197	Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs. <i>Epilepsia</i> , 2002, 43, 37-44.	5.1	126
198	Add-on Phenytoin Fails to Prevent Early Seizures after Surgery for Supratentorial Brain Tumors: A Randomized Controlled Study. <i>Epilepsia</i> , 2002, 43, 175-182.	5.1	112

#	ARTICLE	IF	CITATIONS
199	Overtreatment in epilepsy: adverse consequences and mechanisms. <i>Epilepsy Research</i> , 2002, 52, 25-33.	1.6	55
200	What can we learn from clinical trials of anticonvulsant drugs in epilepsy?. <i>European Journal of Pain</i> , 2002, 6, 35-44.	2.8	16
201	Harnessing the Clinical Potential of Antiepileptic Drug Therapy. <i>CNS Drugs</i> , 2001, 15, 609-621.	5.9	78
202	Single-Dose Pharmacokinetics of Lamotrigine in Children: Influence of Age and Antiepileptic Comedication. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 217-222.	2.0	31
203	Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. <i>Psychopharmacology</i> , 2001, 153, 238-243.	3.1	112
204	Trial duration and follow-up. <i>Epilepsy Research</i> , 2001, 45, 123-127.	1.6	3
205	Trials in women. <i>Epilepsy Research</i> , 2001, 45, 147.	1.6	0
206	Trials in the elderly. <i>Epilepsy Research</i> , 2001, 45, 149-151.	1.6	9
207	The Management of Refractory Idiopathic Epilepsies. <i>Epilepsia</i> , 2001, 42, 31-35.	5.1	38
208	Recent advances in the diagnosis and treatment of epilepsy. <i>European Journal of Neurology</i> , 2001, 8, 519-539.	3.3	19
209	Assessing risk to benefit ratio in antiepileptic drug therapy. <i>Epilepsy Research</i> , 2000, 41, 107-139.	1.6	107
210	The New Antiepileptic Drugs Pharmacological and Clinical Aspects. <i>Current Pharmaceutical Design</i> , 2000, 6, 839-860.	1.9	50
211	Is There a Role for Therapeutic Drug Monitoring of New Anticonvulsants?. <i>Clinical Pharmacokinetics</i> , 2000, 38, 191-204.	3.5	135
212	Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. <i>Epilepsy Research</i> , 1999, 33, 247-262.	1.6	65
213	Enantioselective pharmacokinetics of 10-hydroxycarbamazepine after oral administration of oxcarbazepine to healthy Chinese subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 547-553.	4.7	68
214	The Clinical Pharmacokinetics of the New Antiepileptic Drugs. <i>Epilepsia</i> , 1999, 40, S7-S13.	5.1	90
215	Reversible Pseudoatrophy of the Brain and Mental Deterioration Associated with Valproate Treatment. <i>Epilepsia</i> , 1998, 39, 27-32.	5.1	219
216	Pharmacoresistance in Epilepsy. <i>CNS Drugs</i> , 1998, 10, 171-179.	5.9	87

#	ARTICLE	IF	CITATIONS
217	A PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG. Pharmacological Research, 1997, 35, 241-256.	7.1	152
218	Pharmacologic Advantages of Antiepileptic Drug Monotherapy. Epilepsia, 1997, 38, S6.	5.1	175
219	Evaluation of drug treatment outcome in epilepsy: a clinical perspective. , 1997, 19, 217-222.		18
220	Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy*. Clinical Pharmacology and Therapeutics, 1997, 61, 442-449.	4.7	41
221	The Clinical Pharmacokinetics of the Newer Antiepileptic Drugs. Clinical Pharmacokinetics, 1996, 31, 29-46.	3.5	156
222	Clinically Significant Pharmacokinetic Drug Interactions with Carbamazepine. Clinical Pharmacokinetics, 1996, 31, 198-214.	3.5	284
223	Pharmacokinetic Profile of Topiramate in Comparison with Other New Antiepileptic Drugs. Epilepsia, 1996, 37, S8-S13.	5.1	36
224	The new generation of antiepileptic drugs: advantages and disadvantages. British Journal of Clinical Pharmacology, 1996, 42, 531-543.	2.4	115
225	The new generation of antiepileptic drugs: advantages and disadvantages. British Journal of Clinical Pharmacology, 1996, 42, 531-543.	2.4	144
226	The Management of Epilepsy in the 1990s. Drugs, 1995, 49, 680-694.	10.9	56
227	Clinical Pharmacokinetics of Fluvoxamine. Clinical Pharmacokinetics, 1994, 27, 175-190.	3.5	69
228	Newer and Older Antidepressants. CNS Drugs, 1994, 2, 479-497.	5.9	26
229	Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clinical Pharmacology and Therapeutics, 1994, 56, 471-476.	4.7	93
230	Quantitative comparison of barbiturates in essential hand and head tremor. Movement Disorders, 1991, 6, 65-68.	3.9	37
231	Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. , 1987, 33, 139-144.		56
232	Drug metabolism in pregnancy, infancy and childhood. , 1987, 34, 129-143.		47
233	Free and Total Serum Concentrations of Carbamazepine and Carbamazepine-10, 11-Epoxy in Infancy and Childhood. Epilepsia, 1985, 26, 320-322.	5.1	21
234	Interpretation of Drug Levels in Acute and Chronic Disease States. Clinical Pharmacokinetics, 1985, 10, 498-513.	3.5	29

#	ARTICLE	IF	CITATIONS
235	Free Concentration of Carbamazepine and Carbamazepine-10,11-Epoxyde in Children and Adults. <i>Clinical Pharmacokinetics</i> , 1985, 10, 524-531.	3.5	29
236	In vivo plasma protein binding interaction between valproic acid and naproxen. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1984, 9, 359-363.	1.6	11
237	Diurnal Fluctuations in Free and Total Plasma Concentrations of Carbamazepine at Steady-State and Correlation with Intermittent Side Effects in Epileptic Patients. <i>Clinical Pharmacokinetics</i> , 1984, 9, 93-94.	3.5	2
238	Diurnal Fluctuations in Free and Total Steady-State Plasma Levels of Carbamazepine and Correlation with Intermittent Side Effects. <i>Epilepsia</i> , 1984, 25, 476-481.	5.1	85
239	Free Fraction of Valproic Acid: In Vitro Time-Dependent Increase and Correlation with Free Fatty Acid Concentration in Human Plasma and Serum. <i>Epilepsia</i> , 1983, 24, 65-73.	5.1	105
240	Pharmacokinetic Interactions with Antiepileptic Drugs. <i>Clinical Pharmacokinetics</i> , 1982, 7, 57-84.	3.5	83
241	Plasma Protein Binding of Drugs in Pregnancy. <i>Clinical Pharmacokinetics</i> , 1982, 7, 336-352.	3.5	119
242	Drug Interactions with Phenytoin. <i>Drugs</i> , 1981, 21, 120-137.	10.9	34
243	Plasma Protein Binding of Phenytoin in Health and Disease. <i>Therapeutic Drug Monitoring</i> , 1980, 2, 331-344.	2.0	46
244	Drug interactions in epilepsy. <i>Arquivos De Neuro-Psiquiatria</i> , 1980, 38, 331-340.	0.8	0
245	Interpretation of Drug Levels: Relevance of Plasma Protein Binding. <i>Novartis Foundation Symposium</i> , 1980, , 51-68.	1.1	6
246	Management of Side-Effects of Antiepileptic Drugs. , 0, , 289-299.		4
247	Reproductive Aspects of Epilepsy Treatment. , 0, , 323-333.		1
248	Management of Epilepsy in People with Learning Disabilities. , 0, , 219-229.		2
249	General Principles of Medical Management. , 0, , 119-139.		4
250	Management of Chronic Active Epilepsy in Adults. , 0, , 153-162.		2
251	Management of Epilepsy in Infants. , 0, , 171-178.		1
252	Management of Childhood Epilepsy Syndromes. , 0, , 179-194.		2

#	ARTICLE	IF	CITATIONS
253	Emergency Treatment of Seizures and Status Epilepticus. , 0 , 231-247.		1
254	Traumatic Brain Injury and Other Risks. , 0 , 249-257.		2
255	Epidemiology and Prognosis of Epilepsy. , 0 , 21-31.		5
256	Medical Treatment of Epilepsy in Situations with Limited Resources. , 0 , 379-385.		2
257	Aetiology of Epilepsy. , 0 , 33-53.		3
258	Introduction to the Choice of Antiepileptic Drugs. , 0 , 387-398.		1
259	Adrenocorticotrophic Hormone and Corticosteroids. , 0 , 411-419.		2
260	Benzodiazepines used Primarily for Emergency Treatment (Diazepam, Lorazepam and Midazolam). , 0 , 431-446.		5
261	Differential Diagnosis of Epilepsy. , 0 , 55-66.		2
262	Retigabine. , 0 , 637-646.		4
263	Rufinamide. , 0 , 647-655.		5
264	Antiepileptic Drug Discovery. , 0 , 81-89.		2
265	Invasive EEG in Presurgical Evaluation of Epilepsy. , 0 , 767-798.		15
266	MRI in the Presurgical Evaluation. , 0 , 805-820.		6
267	Experimental Neurophysiological Techniques. , 0 , 829-849.		3
268	Neuropsychological Testing in Presurgical Evaluation. , 0 , 851-863.		4
269	Mechanisms of Antiepileptic Drug Action. , 0 , 91-108.		5
270	Mechanisms of Tolerance and Drug Resistance. , 0 , 109-118.		26



#	ARTICLE	IF	CITATIONS
271	Vagal Nerve Stimulation. , 0 , 1017-1023.		3
272	Management of Newly Diagnosed Epilepsy. , 0 , 141-151.		2
273	Management of Epilepsy in Remission. , 0 , 163-169.		1
274	Management of Epilepsies Associated with Specific Diseases in Children. , 0 , 195-201.		2
275	Management of Epilepsy in the Elderly. , 0 , 203-217.		1
276	Management of Medical Co-morbidity Associated with Epilepsy. , 0 , 259-272.		3
277	Psychiatric Features of Epilepsy and their Management. , 0 , 273-287.		5
278	Ketogenic Diets. , 0 , 301-310.		1
279	Non-pharmacological, Complementary and Alternative Treatments for Epilepsy. , 0 , 311-322.		1
280	Epilepsy Counselling. , 0 , 335-340.		1
281	Genetic Counselling in Epilepsy. , 0 , 341-360.		1
282	Benzodiazepines used Primarily for Chronic Treatment (Clobazam, Clonazepam, Clorazepate and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
283	Carisbamate. , 0 , 475-484.		1
284	Felbamate. , 0 , 511-518.		2
285	On-Line Solid Phase Extraction High Performance Liquid Chromatography Method Coupled With Tandem Mass Spectrometry for the Therapeutic Monitoring of Cannabidiol and 7-Hydroxy-cannabidiol in Human Serum and Saliva. Frontiers in Pharmacology, 0, 13, .	3.5	4